Skip to main content
SpringerLink
Log in

Cancer immunotherapy

Epigenetic checkpoints regulate the fate and function of CAR-T cells

  • News & Views
  • Published:

From Nature Immunology

View current issue Submit your manuscript

T cells exist in many functional states, and dynamic transitions from one state to another affect the outcome of adoptive T cell therapy. FOXP1 and KLF2 are now identified as transcriptional regulators of the stemness of CD8+ CAR-T cells and the bifurcation of stem-like CD8+ CAR-T cells into effector and exhausted subsets, respectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: FOXP1 and KLF2 are key regulators of CAR-T cell fate.

References

  1. Jiang, P. et al. Leukemia 36, 2656–2668 (2022).

    Article  CAS  PubMed  Google Scholar 

  2. Riegel, D. et al. Mol. Cell 83, 622–636.e10 (2023).

    Article  CAS  PubMed  Google Scholar 

  3. Zhu, Z. et al. Nat. Immunol. https://doi.org/10.1038/s41590-023-01685-w (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Tsui, C. et al. Nature 609, 354–360 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Locke, F. L. et al. Lancet Oncol. 20, 31–42 (2019).

    Article  CAS  PubMed  Google Scholar 

  6. Qi, C. et al. Nat. Med. 28, 1189–1198 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chen, G. M. et al. Cancer Discov. 11, 2186–2199 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gueguen, P. et al. Sci Immunol. 6, eabd5778 (2021).

    Article  CAS  PubMed  Google Scholar 

  9. Arcangeli, S. et al. J. Clin. Invest. 132, e150807 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Melenhorst, J. J. et al. Nature 602, 503–509 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. You, L. et al. Front. Immunol. 11, 1787 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Gambacorta, V. et al. Cancer Discov. 12, 1449–1461 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Innovative Immunotherapies Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Monica Casucci

  2. Università Vita-Salute San Raffaele, Milano, Italy

    Chiara Bonini

  3. Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Chiara Bonini & Eliana Ruggiero

Authors
  1. Monica Casucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiara Bonini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eliana Ruggiero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eliana Ruggiero.

Ethics declarations

Competing interests

M.C., C.B. and E.R. are inventors on different patents on cancer immunotherapy and genome editing (E.R.: PCT/EP2018/060477, PCT/EP2019/079916 and PCT/EP2022/053040; C.B.: PCT/IT2006/000600, 12/927,292, PCT/US2014/031360, PCT/IB2015/057049, PCT/EP2018/060477, PCT/EP2019/079916, PCT/EP2021/061198 and PCT/EP2022/053040; M.C.: PCT/IB2015/057049, PCT/EP2021/061198 and PCT/EP2019/069712). M.C. has received research support from Kite/Gilead. C.B. has been a member of advisory boards and a consultant for Intellia Therapeutics, TxCell, Novartis, GSK, Allogene, Kite/Gilead, Miltenyi, Kiadis and Janssen, and received research support from Intellia Therapeutics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Casucci, M., Bonini, C. & Ruggiero, E. Epigenetic checkpoints regulate the fate and function of CAR-T cells. Nat Immunol 25, 4–6 (2024). https://doi.org/10.1038/s41590-023-01708-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-023-01708-6

  • Springer Nature America, Inc.

Search

Navigation